Conversations about health AI over the past few years have focused heavily on model capability: whether the algorithm is advanced enough, whether performance is strong enough, and whether the product can clear a regulatory path. But as we move deeper into 2026, a more fundamental shift is taking place. For many health AI products, the real differentiator is no longer simply whether the model looks strong. It is whether the product can continuously build and demonstrate real-world evidence. That is increasingly becoming the new gatekeeper.
Why does this matter more now? Because health AI is moving from “it appears to work in development” to “it must remain reliable in real clinical environments.” Once an AI system enters real use, it immediately faces variation across institutions, patient populations, equipment, workflows, and post-launch change. The core question is no longer only how the system performs on a training or validation dataset. It is whether performance remains stable, controllable, and interpretable across real settings.
That is why real-world evidence is shifting from a nice-to-have to a threshold requirement. Once health AI enters more serious clinical and commercial environments, hospitals, physicians, partners, and regulators care about at least four things: Does it still hold across institutions? Does it degrade when patient populations change? Does it improve outcomes in practice, or create new forms of bias? After updates, can it still be monitored, validated, and controlled? None of those questions can be answered by a one-time study or a single dataset alone.
This shift is especially important for Chinese health AI companies. Many teams have already built early models, completed initial validation, and started commercial efforts in their home market. But if the next goal is the U.S. market, simply “having a model” is no longer enough. The U.S. market increasingly cares not only about whether the technology is advanced, but whether it can build durable trust in real clinical settings. In other words, the next stage of competition in health AI will not be defined by who speaks best about AI, but by who builds evidence earlier and more seriously.
This is also why BioLife no longer views health AI simply as a matter of exporting algorithms or selling software. We are increasingly focused on a deeper set of questions: Does the system have a clear application scenario? Can it find the right research-first entry or market-entry pathway? Can it establish real-world evidence support? Can it build a stronger U.S. market foundation through clinical data collaboration, research validation, and evidence generation?
In that sense, real-world evidence is no longer an additional layer of explanation for health AI. It is becoming a new gatekeeper for whether a product can go further. The earlier a company understands that, the more likely it is to occupy a higher-quality position in the next stage of competition.
